Physician profile
Michael James Tagge
NPI 1326622341
$3,221.98
in general payments reported to CMS, 2019-2025
7 companies · $2,372 in 2025
The $2,372 reported for 2025 was more than what 95% of Foot Surgery providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $184 · 2024: $665 · 2025: $2,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,683 · Travel and Lodging: $1,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,682.87 |
| Travel and Lodging | $1,539.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $2,349.91 | 2024-2025 | Pico, Grafix, Collagenase Santyl |
| Stryker Corporation | $239.47 | 2023-2024 | Actishield, Augment Injectable, Allopure |
| Treace Medical Concepts, INC. | $216.53 | 2024-2025 | |
| Kerecis Limited | $114.37 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Orthofix Medical, INC. | $113.29 | 2024 | Physio-Stim |
| Medshape, INC. | $98.42 | 2024 | Morphix, Dynanail Helix, Washer, 15 Mm, Dynanail |
| Organogenesis INC. | $89.99 | 2024 | Puraply Wound Matrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tagge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.